Search for stocks /

GSM Foils: 604% Profit Growth, 243% Stock Return — Is This Pharma Wrapper Actually the Main Drug?

1. At a Glance

Founded in 2019, GSM Foils makes blister foils and aluminium pharma foils. Basically, they manufacture the thing you angrily press to pop a Crocin out. Stock listed on NSE SME in May 2024 at ₹32 issue price, today at ₹225 — a 7x jump. Sales zoomed from ₹27 Cr (Dec ’23 half-year) to ₹165 Cr TTM. Profits exploded 6x. But beware: cash flows are negative, debt is creeping up, and board meetings keep getting postponed like a college fest in monsoon.

2. Introduction

SME IPOs are usually “cousin’s coaching class” level businesses that list and fizzle. GSM Foils is different. In one year, it went from nobody to SME superstar — 243% stock return, ROE/ROCE ~46%, and fat margins in a boring industry.

The product? Foils that protect medicines from air, light, and moisture. Without these, your paracetamol would turn into chalk powder. In pharma supply chain, foils are the unsung heroes. But in stock market, GSM has suddenly become the star kid, while older players like Uflex and Cosmo are struggling with flat growth.

So, is this company a future “SME to mainboard rocket,” or just a shiny wrapper with hollow chocolate inside?

3. Business Model (WTF Do They Even Do?)

Blister Foils: For tablets/capsules — push-through, peel-push, tear-open varieties.
Aluminium Strip Pharma Foils: Higher barrier for sensitive drugs.
Manufacturing Facility: Thane, ISO 9001 certified, 15,000 sq. ft. — small but efficient.
Clients: Pharma companies needing safe, regulated packaging.

In short: if pharma is Bollywood, GSM Foils is the guy who makes the camera lens covers. Essential, but invisible.

4. Financials Overview

Source table

Metric	Q1 FY26	Q1 FY25	Q4 FY25	YoY %	QoQ %
Revenue	₹52 Cr	₹21 Cr	₹45.6 Cr	+148%	+14%
EBITDA	₹5.8 Cr	₹2.1 Cr	₹5.8 Cr	+170%	0%
PAT	₹3.83 Cr	₹1.40 Cr	₹3.42 Cr	+174%	+12%
EPS	₹2.99	₹1.09	₹2.67	+174%	+12%

Annualised EPS = ₹12.0
At CMP ₹225 → P/E ~18.7x, cheaper than reported 23.8x because Q1 was strong.

Comment: Revenues are scaling like a cricket score in a T20 powerplay. Profits following suit.

5. Valuation (Fair Value Range Only)

P/E Method: EPS ~₹12 (annualised), apply SME packaging sector multiple 20–25 → FV = ₹240–₹300.
EV/EBITDA: EV ~₹306 Cr, EBITDA ~₹19 Cr → EV/EBITDA ~16x. Industry ~15–18x. FV = ₹200–₹280.
DCF (15% growth, 12% discount, 5 years): FV = ₹220–₹280.

Consolidated FV Range = ₹200 – ₹300
(Educational purposes only, not investment advice)

6. What’s Cooking – News, Triggers, Drama

Rights Issue: Company approved ₹23.1 Cr rights issue (pending NSE nod). Purpose: working capital + expansion. Investors hate dilution, but expansion needs fuel.
Loan Facility: Took ₹20 Cr working capital loan from DCB Bank in Jan 2025.
Capacity Build-up: Strong sales trajectory suggests either capacity utilization >80% or aggressive client onboarding.
Market Buzz: Stock already gave 243% in 1

To Read Full 16 Point